Tetanus toxoid peptide-MHC class II complex (TT-MHC II)

Tetanus toxoid peptide epitopes presented on MHC class II molecules are essential mediators of the secondary immune response in humans (Panina-Bordignon et al., 1989, Eur. J. Immunol.). These epitopes are short peptide fragments, such as the well-characterized P2 and P30 sequences, derived from the tetanus toxin produced by Clostridium tetani (UniProt P04958). Once processed by professional antigen-presenting cells, they are loaded onto MHC class II molecules and displayed on the cell surface for recognition by CD4+ T-cell receptors (Janeway's Immunobiology, 2001). Due to the near-universal prevalence of tetanus vaccination, these complexes serve as potent triggers for memory T-cell activation (CDC, 2023). In clinical applications, they are often used as carrier proteins or helper epitopes in conjugate vaccines and cancer immunotherapies to recruit T-cell help and boost the overall immune response against a linked antigen (Pollack et al., 2020, J. Immunother. Cancer).

Other names

Tetanus toxoid epitopesTT-derived peptidesP2 and P30 epitopesMHC II-restricted tetanus toxoid peptidesTetanus toxin-derived helper epitopesTT-pMHC II

The complex acts as a ligand for the T-cell receptor (TCR) on CD4+ T lymphocytes. Recognition of the TT peptide-MHC II complex by a cognate TCR, in the presence of co-stimulatory signals, triggers T-cell activation, proliferation, and the production of helper cytokines such as IL-2 and IFN-gamma, which are essential for robust B-cell antibody production and CD8+ T-cell cytotoxic activity (Janeway's Immunobiology, 2001; Panina-Bordignon et al., 1989).